Table 4.

Baseline Characteristics, ESA dose, and Hb Response by smoking status and Treatment Group¹

	Current Smokers		NonSmokers/Past Smokers
	High Hb [13.5 g/dL] target (n=40)	Low Hb [11.3 g/dL] target (n=50)	High Hb [13.5 g/dL] target (n=668)	Low Hb [11.3 g/dL] target (n=660)
Age	61.7 ± 14.4	62.2 ± 11.7	66.2 ± 14.3	66.6 ± 13.6
Comorbidity     Atrial fibrillation/flutter     Diabetes mellitus     Coronary artery disease     Cerebrovascular disease     Heart failure	2/38 (5.3%) 26/39 (66.7%) 13/38 (34.2%) 9/38 (23.7%) 11/38 (28.9%)	4/49 (8.2%) 27/50 (54.0%) 10/49 (20.4%) 10/49 (20.4%) 11/49 (22.4%)	61/628 (9.7%) 407/666 (61.1%) 218/629 (34.7%) 78/630 (12.4%) 179/628 (28.5%)	54/618 (8.7%) 425/659 (64.5%) 204/619 (33.0%) 88/616 (14.3%) 170/618 (27.5%)
ESA dose (U/wk)2	10,408.2 [7060.5–13149.5]	5,493.0 [3412.1–7866.0]	10,840.7 [7724.8–14204.2]	4,498.5 [2942.6–7379.2]
Achieved Hb target by month 4	19/39 (48.7%)	47/50 (94.0%)	390/662 (58.9%)	606/652 (92.9%)
Achieved Hb target by the CKD endpoint 3	27/35 (77.1%)	44/46 (95.7%)	530/623 (85.1%)	598/614 (97.4%)

Values for continuous variables given as mean ± SD or median [25^th–75^th percentile]; values for categorical variables given as n/N (%).

ESA, erythropoiesis-stimulating agent; CKD, chronic kidney disease; Hb, hemoglobin

¹Three of the 1,421 participants were missing smoking status and were not included in this table

²ESA dose was defined as the sum of EPO doses from baseline through the day of kidney disease progression endpoint divided by the number of weeks of follow-up

³Defined as the maximum Hb after day 1 through the day of the kidney disease progression endpoint >=13.1 g/dL if the target Hb group = 13.5 or >=11.1 g/dL if the target Hb group = 11.3